search
Back to results

Intraoperative Aromatherapy Versus Placebo for Port-a-Cath Placement Under Monitored Anesthesia Care. A Randomized Controlled Trial

Primary Purpose

Cancer Pain

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
ELEQUIL
Sponsored by
M.D. Anderson Cancer Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Cancer Pain

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult patients (≥ 18 years old)
  • Port-a-Cath placement under Monitored Anesthesia Care
  • Signed informed consent

Exclusion Criteria:

  • Patients undergoing other surgical procedures during Port-a-Cath placement (including explantation of a Port-a-Cath or other previous vascular access device)
  • Patients requiring general anesthesia or those not eligible for MAC

Sites / Locations

  • MD Anderson Cancer CenterRecruiting

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

ELEQUIL

Arm Description

Aromatherapy will be provided using a lavender-peppermint patch called an Aromatab.

Outcomes

Primary Outcome Measures

To compare the time to readiness for discharge from PACU (minutes) after Port-a-Cath placement surgery between patients who are randomized to receive intraoperative aromatherapy versus placebo

Secondary Outcome Measures

Full Information

First Posted
April 5, 2022
Last Updated
May 25, 2023
Sponsor
M.D. Anderson Cancer Center
search

1. Study Identification

Unique Protocol Identification Number
NCT05328973
Brief Title
Intraoperative Aromatherapy Versus Placebo for Port-a-Cath Placement Under Monitored Anesthesia Care. A Randomized Controlled Trial
Official Title
Intraoperative Aromatherapy Versus Placebo for Port-a-Cath Placement Under Monitored Anesthesia Care. A Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 18, 2022 (Actual)
Primary Completion Date
September 30, 2024 (Anticipated)
Study Completion Date
September 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
M.D. Anderson Cancer Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a prospective, controlled, randomized trial. Primary objective is to compare the time to readiness for discharge (minutes) from Post-Anesthesia Care Unit (PACU) after Port-a-Cath placement surgery between patients who are randomized to receive intraoperative aromatherapy versus placebo. 70 Eligible subjects will be identified from within the patient population of the study site. There will be no advertisements for study subjects.
Detailed Description
Primary Objective: To compare the time to readiness for discharge (minutes) from Post-Anesthesia Care Unit (PACU) after Port-a-Cath placement surgery between patients who are randomized to receive intraoperative aromatherapy versus placebo. Secondary Objective: To evaluate the following secondary outcomes: Anxiety score (HADS) in preoperative holding area Midazolam use intraoperatively (mg) Itraoperative opioid use (morphine equivalents) Intraoperative anti-emetic use Time to first occurrence of postoperative nausea or vomiting (PONV) in PACU Rate and intensity of PONV in PACU Antiemetic use in PACU Opioid use in PACU (morphine equivalents) Pain intensity in PACU (0-10 numerical rating scale) Patient satisfaction in PACU

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cancer Pain

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
70 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ELEQUIL
Arm Type
Other
Arm Description
Aromatherapy will be provided using a lavender-peppermint patch called an Aromatab.
Intervention Type
Other
Intervention Name(s)
ELEQUIL
Other Intervention Name(s)
Aromatabs
Intervention Description
patch placed on skin
Primary Outcome Measure Information:
Title
To compare the time to readiness for discharge from PACU (minutes) after Port-a-Cath placement surgery between patients who are randomized to receive intraoperative aromatherapy versus placebo
Time Frame
through study completion, an average of 1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult patients (≥ 18 years old) Port-a-Cath placement under Monitored Anesthesia Care Signed informed consent Exclusion Criteria: Patients undergoing other surgical procedures during Port-a-Cath placement (including explantation of a Port-a-Cath or other previous vascular access device) Patients requiring general anesthesia or those not eligible for MAC
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Neil Bailard, MD
Phone
(713) 597-1687
Email
nbailard@mdanderson.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Neil Bailard, MD
Organizational Affiliation
M.D. Anderson Cancer Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Neil Bailard, MD
Phone
713-597-1687
Email
nbailard@mdanderson.org
First Name & Middle Initial & Last Name & Degree
Neil Bailard, MD

12. IPD Sharing Statement

Links:
URL
http://www.mdanderson.org
Description
M D Anderson Cancer Center

Learn more about this trial

Intraoperative Aromatherapy Versus Placebo for Port-a-Cath Placement Under Monitored Anesthesia Care. A Randomized Controlled Trial

We'll reach out to this number within 24 hrs